biotech · Ovarian Clear Cell Carcinoma · Tumors · LIXT
LIXTE BIOTECHNOLOGY HOLDINGS
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Lixte Biotechnology Holdings is a biotech organization headquartered in East Setauket, USA. It trades on NYSE under ticker LIXT. Primary therapeutic focus areas include Ovarian Clear Cell Carcinoma, Tumors, Myelodysplast
East Setauket, USA HQ
2006 Founded
7 Employees
Public company Type
LIXT · NYSE Ticker
Company details
- Status
- Public
- HQ
- East Setauket, USA
- Founded
- 2006
- Employees
- 7
- Programs
- 3
- Drugs
- 3
- Patents
- 26
Dostarlimab
Phase 2 · small molecule · Ovarian Clear Cell Carcinoma
Dostarlimab for Ovarian Clear Cell Carcinoma is a Phase 2 program (small_molecule) at LIXTE BIOTECHNOLOGY HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Internal code 2022-1047
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Ovarian Clear Cell Carcinoma
- Status
- active
- Trials
- 1